In the BioHarmony Drug Report Database
Lisdexamfetamine
Vyvanse (lisdexamfetamine) is a small molecule pharmaceutical. Lisdexamfetamine was first approved as Vyvanse on 2007-02-23. It is used to treat attention deficit disorder with hyperactivity and binge drinking in the USA. Vyvanse’s patent is valid until 2023-02-24 (FDA).
Trade Name
|
Vyvanse |
|---|---|
Common Name
|
lisdexamfetamine |
ChEMBL ID
|
CHEMBL1201222 |
Indication
|
attention deficit disorder with hyperactivity, binge drinking |
Drug Class
|
Amfetamine derivatives |
Image (chem structure or protein)